Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: Are there blood pressure-independent effects?

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 12, 2010, Pages 1159-1169

  Kujal, Petr ^a,b,c   Chábová, Věra Čertíková ^a,c,d   Vernerová, Zdenka ^b   Walkowska, Agnieszka ^b   Kompanowska Jezierska, Elzbieta ^b   Sadowski, Janusz ^b   Vaňourková, Zdeňka ^a,c   Husková, Zuzana ^a,c   Opočenskỳ, Martin ^a   Škaroupková, Petra ^a   Schejbalová, Stanislava ^a   Kramer, Herbert J ^e   Rakušan, Dan ^a,c   Malỳ, Jan ^a   Netuka, Ivan ^c   Vaněčková, Ivana ^c   Kopkan, Libor ^a,c   Červenka, Luděk ^a,b,c  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Center for Cardiovascular Research   (Czech Republic)

^d MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

Alpha and beta adrenergic receptor antagonist; Angiotensin converting enzyme inhibitor; Angiotensin II receptor antagonist type 1; End organ damage; Glomerulosclerosis; Hypertension; Renin angiotensin aldosterone system; Renoprotection

Indexed keywords

FUROSEMIDE; HYDROCHLOROTHIAZIDE; LABETALOL; LOSARTAN; TRANDOLAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY FAILURE; KIDNEY TUBULE DAMAGE; MALE; NEPHRECTOMY; NONHUMAN; PROTEINURIA; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOMEGALY; CHYMOSIN; CREATININE; DIABETIC NEPHROPATHIES; DIURETICS; DRUG THERAPY, COMBINATION; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYPERTENSION; INDOLES; KIDNEY FAILURE, CHRONIC; LABETALOL; LOSARTAN; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 78649737456     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05453.x     Document Type: Article

References (55)

1. US Renal Data System: USRDS. 2007 Chronic kidney disease. Am. J. Kidney Dis. 2008; 51: S63-80.
2. Bakris GL, Ritz E. The message for World Kidney Day 2009: Hypertension and kidney disease: A marriage that should be prevented. J. Clin. Hypertens. 2009; 11: 144-7.
3. Hostetter TH, Olson JL, Rennke HG, Ventatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: A potentially adverse response to ablation. Am. J. Physiol. 1981; 241: F85-93.
4. Brenner BM. Nephron adaptation to renal injury or ablation. Am. J. Physiol. 1985; 249: F324-37.
5. Zoja C, Abbate M, Remuzzi G. Progression of chronic kidney disease: Insight from animal models. Curr. Opin. Nephrol. Hypertens. 2006; 15: 250-7.
6. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 2006; 116: 288-296.
7. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal diseases associated with systemic hypertension in the rat. J. Clin. Invest. 1986; 77: 1993-2000.
8. Bidani AK, Griffin KA, Picken M, Lansky DM. Continuous telemetric blood pressure monitoring and glomerular injury in the rat remnant model. Am. J. Physiol. 1993; 265: F391-8.
9. Taal MW, Chertow GM, Rennke HG et al. Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am. J. Physiol. 2001; 280: F343-55.
10. Velaz JC. The importance of the intrarenal renin-angiotensin system. Nat. Clin. Pract. Nephrol. 2008; 2: 89-100.
11. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 2007; 59: 251-87.
12. Rüster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J. Am. Soc. Nephrol. 2006; 17: 2985-91.
13. Velkoska E, Dean RG, Burchill L, Levidiotis V, Burrell LM. Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clin. Sci. 2010; 118: 269-79.
14. Macconi D. Targeting the renin angiotensin system for remission/regression of chronic kidney disease. Histol. Histopathol. 2010; 25: 655-68.
15. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int. 2000; 57: 1803-17.
16. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int. 1992; 42: 46-55.
17. Adamczak M, Gross ML, Krtil J et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J. Am. Soc. Nephrol. 2003; 14: 2833-42.
18. Bidani AK, Griffin KA, Bakris G, Picken MM. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int. 2000; 57: 1651-61.
19. Griffin KA, Abu-Amarah I, Picken MM, Bidani AK. Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension 2003; 41: 201-6.
20. Griffin KA, Picken MM, Bidani AK. Blood pressure lability and glomerulosclerosis after normotensive 5/6 renal mass reduction in rat. Kidney Int. 2004; 65: 209-18.
21. Loutzenhiser R, Griffin KA, Williamson G, Bidani AK. Renal autoregulation: New perspectives regarding the protective and regulatory roles of the underlying mechanisms. Am. J. Physiol. 2006; 290: 1153-7.
22. Mackie FE, Campbell DJ, Meyer TW. Intrarenal angiotensin and bradykinin peptide levels in the remnant kidney model of renal insufficiency. Kidney Int. 2001; 59: 1458-65.
23. Mackie FE, Meyer TW, Campbell DJ. Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency. Kidney Int. 2002; 62: 555-63.
24. 1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J. Pharmacol. Exp. Ther. 2007; 323: 85-93.
25. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harboring the mouse Ren-2 gene. Nature 1990; 344: 541-4.
26. Husková Z, Kramer HJ, Vaňourková Z, Červenka L. Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J. Hypertens. 2006; 24: 517-27.
27. Kopkan L, Husková Z, Vaňourková Z et al. Reduction of oxidative stress does not attenuate the development of angiotensin II-dependent hypertension in Ren-2 transgenic rats. Vascul. Pharmacol. 2009; 51: 175-81.
28. Lee MA, Böhm M, Paul M, Bader M, Ganten U, Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mRen2)27. Am. J. Physiol. 1990; 270: E919-29.
29. Čertíková Chábová V, Walkowska A, Kompanowska-Jezierska E et al. Combined inhibition of 20-hydroxyeicosatetrenoic acid formation and epoxyeicosatrienoic degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin. Sci. 2010; 118: 617-32.
30. Berl T. Renal protection by inhibition of the renin-angiotensin-aldosterone system. J. Renin Angiotensin Aldosterone Syst. 2009; 10: 1-8.
31. Remmuzi A, Gagliardini E, Donadoni C et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int. 2002; 62: 885-94.
32. Zoja C, Corna D, Camozzi D et al. How to fully protect the kidney in a severe model of progressive nephropathy: A multidrug approach. J. Am. Soc. Nephrol. 2002; 13: 2898-908.
33. Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME. Additive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin. Sci. 2001; 100: 591-9.
34. Azizi M, Ménard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004; 109: 2492-9.
35. Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE. Recommendations for blood pressure measurements in humans and experimental animals. Part 2: Blood pressure measurements in experimental animals. Hypertension 2005; 45: 299-310.
36. 1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J. Hypertens. 2006; 24: 2465-72.
37. Červenka L, Vaněčková I, Husková Z et al. Pivotal role of angiotensin II receptor subtype 1A in the development of two-kidney, one-clip hypertension: Study in angiotensin II receptor subtype 1A knockout mice. J. Hypertens. 2008; 26: 1379-89.
38. Bürgelová M, Vaňourková Z, Thumová M et al. Impairment of the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension. J. Hypertens. 2009; 27: 1988-2000.
39. Erbanová M, Thumová M, Husková Z et al. Impairment of the autoregulation of renal hemodynamics and of the pressure-natriuresis relationship precedes the development of hypertension in Cyp1a1-Ren-2 transgenic rats. J. Hypertens. 2009; 27: 575-86.
40. Husková Z, Vaňourková Z, Erbanová M et al. Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbates hypertension in Cyp1a1-Ren-2 transgenic rats. J. Hypertens. 2010; 28: 495-509.
41. Sandberg MC, Laborde C. Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17-beta-estradiol in the aging Dahl salt sensitive rat. J. Am. Soc. Nephrol. 2004; 15: 1546-56.
42. Nakano Y, Hirano T, Uehara K et al. New rat model induced by anti-glomerular basement membrane antibody shows sever glomerular adhesion in early stage and quickly progresses to end-stage renal failure. Pathol. Int. 2008; 58: 361-70.
43. Cervenka L, Heller J. Comparison of the effects of a low-protein diet with the effects of a converting enzyme inhibitor on the progression of renal insufficiency in hypertensive rats. Ren. Fail. 1996; 18: 173-80.
44. Šochman J, Peregrin JH, Bürgelová M, Kopkan L, Kramer HJ. N-acetylcysteine attenuates iodine contrast agent-induced nephropathy in 5/6-nephrectomized rats. Kidney Blood Press. Res. 2010; 33: 149-56.
45. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 1985; 76: 612-9.
46. Neuringer JR, Brenner BM. Hemodynamic theory of progressive renal diseases. A 10-year update in brief review. Am. J. Kidney Dis. 1993; 22: 98-104.
47. Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I. Effects of antihypertensive drugs on glomerular morphology. Kidney Int. 1989; 36: 626-35.
48. Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes vs. Hypertrophy in experimental glomerular sclerosis. Kidney Int. 1989; 35: 654-60.
49. Ketteler M, Noble NA, Border WA. Transforming growth factor-β and angiotensin II: The missing link from glomerular hyperfiltration to glomerulosclerosis? Annu. Rev. Physiol. 1995; 57: 279-95.
50. Schnermann J, Briggs JP. Function of the juxtaglomerular apparatus: Control of glomerular hemodynamics and renin secretion. In: Seldin DW, Giebisch G (eds). The Kidney: Physiology and Pathophysiology. Lippincott Williams & Wilkins, Philadelphia, 2000; 945-80.
51. Nishimura H, Matsusaka T, Fogo A, Kon V, Ichikawa I. A novel in vivo mechanism for angiotensin type 1 receptor regulation. Kidney Int. 1997; 52: 345-55.
52. 1A receptor knockout mouse during normal and volume-expanded conditions. Kidney Int. 1999; 56: 1855-62.
53. 1 receptor. Am. J. Hypertens. 1998; 11: 570-8.
54. Mori T, Cowley AW Jr. Role of pressure in angiotensin II-induced renal injury. Chronic servo-control of renal perfusion pressure in rats. Hypertension 2004; 43: 752-9.
55. Ihara G, Kiyomoto H, Kobori H et al. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: Effect of angiotensin II blockade. J. Hypertens. 2010; 28: 2289-98.